Adjuvant Capital
@adjcap
Adjuvant Capital is a life sciences venture capital firm focused on public health.
You might like
We are thrilled to announce Adjuvant I, a $300 million vehicle focused on supporting life sciences technologies to address high burden diseases in the developing world. bloomberg.com/news/articles/…
bloomberg.com
Pandemic Stokes Interest in Gates-Backed Public Health Fund
The coronavirus pandemic has shone a spotlight on underfunded public health issues and infectious diseases. Investors once reluctant to put capital toward niche vaccine candidates, diagnostic tools...
Congrats to @adjcap portfolio company Antiva on successfully closing a "rare" Series E financing to advance their potentially game-changing vaginal tablet treatment for pre-cancerous lesions caused by HPV. 👏👏 Excited to work with @MPMCapital and new CEO Kristine Ball to…
Minister of Development Cooperation @carogennez visited the 🇧🇪 Belgian company #Univercells yesterday with 🇰🇪 President @WilliamsRuto & Minister-President of Wallonia @eliodirupo. Read more below ⤵️
The first panel of the day featuring keynotes from @QimingVC @icosavax @adjcap @ArcturusRx @Vaxcyte starts 10:00 AM. Join them in Room 1 for "Raising capital – has the pandemic reignited interest in vaccine & immunotherapy biotechs?" #WVIC #Vaccines
Thrilled to welcome Josh Adeoye to the Adjuvant team in San Francisco! adjuvantcapital.com/news/josh-adeo…
"Our vaccine candidate appears able to block surrogate SARS-CoV-2 replication in the nose before it reaches the lower airways or lungs." 💪💪💪
COVI-VAC, our intranasal #vaccine candidate, shows promising Safety and Immunogenicity results following our Phase 1 Trial. Learn more about our progress on COVI-VAC and how it differentiated compared to other #COVID19 vaccines. #machinelearning #SynBio prnewswire.com/news-releases/…
prnewswire.com
Codagenix Announces Safety and Immunogenicity Data from Phase 1 COVID-19 Intranasal Vaccine Trial...
/PRNewswire/ -- Codagenix Inc., a clinical-stage biotechnology company pioneering a novel platform for vaccines and oncolytic virus therapies, today announced...
Adjuvant portfolio company @VitriVax is hiring a Director of Business Development in Boulder, CO! Apply here: vitrivax.rippling-ats.com/job/266631/dir…
Great to see two @adjcap portfolio companies collaborating on such an important project.
📢 We are pleased to announce a new research collaboration with @Codagenix, Inc. on an undisclosed, high-priority human vaccine target with global public health demand. Read the press release univercells.com/newsroom/codag… #vaccinedevelopment #biologicsforall #globalhealth
linkedin.com
3,000+ Private Equity Associate jobs in United States
Today's top 3,000+ Private Equity Associate jobs in United States. Leverage your professional network, and get hired. New Private Equity Associate jobs added daily.
$2 billion now seems trivial compared to the *trillions* of dollars of economic damage and stimulus costs from #COVID2019. We need a massive global ⬆️ in R&D funding and innovative financing tools, such as prizes, vouchers, stockpiles, or market-entry awards.
“Ending this pandemic, saving lives and protecting societies around the world, depends on science” - @wellcometrust Director @JeremyFarrar We've made an urgent call for $2 billion to support the development of a #COVID19 vaccine⤵️ @thetimes thetimes.co.uk/article/vaccin…
Adjuvant is hiring an experienced investment associate with a technical background for our San Francisco office! linkedin.com/jobs/view/2469…
Watch Adjuvant’s @jennychyip at the @WuXi_AppTec Healthcare Forum!
Starting now, join us for a conversation on Global Solutions for Global Challenges with special guest Adjuvant Capital Managing Partner Jenny Yip and WuXi AppTec’s very own @richsollwx. #WHF2021 Register to watch ➤bit.ly/3tkFxYM cc: @adjcap
Honored to work alongside @grockman, @kpk7767, @kadjuvant, @credibleutility, @serenestazure and the rest of @adjcap to further the "double-bottom-line" mission: invest in the most promising public health technologies and ensure they are made accessible to those who need them most
We are thrilled to announce Adjuvant I, a $300 million vehicle focused on supporting life sciences technologies to address high burden diseases in the developing world. bloomberg.com/news/articles/…
bloomberg.com
Pandemic Stokes Interest in Gates-Backed Public Health Fund
The coronavirus pandemic has shone a spotlight on underfunded public health issues and infectious diseases. Investors once reluctant to put capital toward niche vaccine candidates, diagnostic tools...
“As a company focused on science-based innovation to address some of society's most challenging healthcare issues, we are pleased to invest in @adjcap as part of our holistic global health strategy.” -- Dr. Lutz Hegemann of @Novartis fiercebiotech.com/biotech/gates-…
Congrats to my colleagues @kpk7767, @credibleutility, @lilly_dsb, and Jenny Yip on one of our boldest bets to date: a technology with the potential to cure HIV and other terrible chronic infections. Very excited to begin this journey with @ExcisionBiotx! globenewswire.com/news-release/2…
A look at our growth from @fredmgrier in @SDbusiness. We launched our #COVID19 test + expanded our team, manufacturing capabilities to meet lab testing demand during the pandemic. Looking forward to our growth this year! (Sub req’d) #pcr #diagnostics ow.ly/RFHS50DeHYs
Congrats to our friends at @InDevR_Inc and @biological_e on the development of yet another much-needed innovation in the vaccine characterization space! 💉🔬🙅♀️ measles-rubella 🙅♀️🔬💉 @edtenent prnewswire.com/news-releases/…
prnewswire.com
InDevR Launches VaxArray Measles and Rubella Kit for Improved Vaccine Antigen Characterization
/PRNewswire/ -- InDevR, Inc., a life science tools company providing powerful analytical technologies to support the development and production of vaccines and...
Simply awesome!
A new milestone - over 2 million COVID-19 PCR tests shipped! We reached our second million twice as fast as our first. Now on to helping 3 million people get tested! #COVID19 #SARSCoV2 #diagnostics #pcr
Congratulations to our friends at Univercells on yet another incredible year! Like everyone on the planet, we are even more excited about what 2021 will bring... 🎉 @BiologicsforAll 🎉 lecho.be/entreprises/ph…
We are thrilled to announce that @Themis_Bio has been acquired by @Merck! More here: wsj.com/articles/merck…
United States Trends
- 1. Mike Tomlin N/A
- 2. Scott Adams N/A
- 3. $PIKZ N/A
- 4. Zac Taylor N/A
- 5. AFC North N/A
- 6. Dilbert N/A
- 7. FINALLY DID IT N/A
- 8. The Jupiter N/A
- 9. Pittsburgh N/A
- 10. #TicTacToe2026 N/A
- 11. Clintons N/A
- 12. Deadpool N/A
- 13. Steve Bisciotti N/A
- 14. Arenado N/A
- 15. Jim Jordan N/A
- 16. #IranMassacre N/A
- 17. Cowher N/A
- 18. People Magazine N/A
- 19. Victoria Edel N/A
- 20. #NintendoSwitch2025 N/A
You might like
-
Amee Kapadia
@ameekapadia -
Civilization VC
@CivilizationVC -
Molly Maloof
@mollymaloofmd -
Pablo Ventura
@pablo_ventura -
Amber Tong
@AmberTongPW -
S32
@S32_VC -
Sara Nayeem
@SaraNayeem -
Elizabeth Wood 🧬🖥️🥼
@lizbwood -
David Schenkein
@schenkein -
Michael Gladstone
@MikeNGladstone -
Shahram Seyedin-Noor
@ShahramSN -
DCVC Bio
@DCVCBio
Something went wrong.
Something went wrong.